Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Venlafaxine hydrochloride
Drug ID BADD_D02347
Description Venlafaxine (Effexor) is an antidepressant within the serotonin-norepinephrine reuptake inhibitor (SNRI) class of medications. It exerts its effects primarily by blocking the transporters involved in the reuptake of the neurotransmitters serotonin and norepinephrine, therefore leaving more active neurotransmitter in the synapse. Venlafaxine is officially approved for use in the management of major depressive disorder (MDD), generalized anxiety disorder (GAD), social anxiety disorder, and panic disorder. As of 2014, Canadian clinical practice guidelines recommend venlafaxine as a first-line option for treatment of generalized anxiety, social anxiety, panic disorder, major depressive disorder (MDD), and consider it a second-line option for management of obsessive-compulsive disorder (OCD) [A177226,A177235]. Venlafaxine is also used off-label for prophylaxis of migraine headaches [A177229], for reduction of vasomotor symptoms associated with menopause [A177238], and for management of neuropathic pain (although there is only minimal evidence of efficacy for this condition) [A177232].
Indications and Usage For the management of major depressive disorder (MDD), generalized anxiety disorder (GAD), social anxiety disorder (social phobia), panic disorder with or without agoraphobia, vasomotor symptoms in women with breast cancer and in postmenopausal women, and neuropathic pain.
Marketing Status Prescription; Discontinued
ATC Code N06AX16
DrugBank ID DB00285
KEGG ID D00821
MeSH ID D000069470
PubChem ID 62923
TTD Drug ID D0P1UX
NDC Product Code 70518-3136; 68071-5064; 0093-9149; 64679-718; 35356-791; 55111-547; 65862-527; 65841-752; 53002-2365; 47335-794; 45865-643; 57237-176; 70518-2933; 67046-560; 70934-735; 33342-196; 0904-6468; 68071-4164; 55700-887; 50090-5891; 68025-080; 55700-813; 13811-714; 68382-036; 68084-709; 65841-675; 68084-698; 68071-5160; 68788-7919; 42291-895; 53002-1365; 65841-751; 50268-817; 50090-5731; 68071-2393; 42816-0837; 68788-7891; 50090-5748; 71335-1104; 71335-1338; 65691-0126; 31722-002; 71335-1317; 63187-481; 70518-0558; 45865-647; 0093-9148; 52343-131; 71335-0563; 70518-1976; 50090-2281; 68025-082; 50268-819; 65841-753; 64679-717; 42708-054; 13811-713; 0093-9157; 47335-759; 43353-234; 68382-035; 68069-0002; 58118-0335; 53002-1366; 68071-5020; 50090-4587; 68788-8072; 70518-2587; 71610-013; 68788-6806; 43353-233; 31722-003; 0615-8346; 0093-9163; 50771-001; 13811-712; 16714-038; 71335-1993; 0904-6469; 65691-0036; 60429-866; 0008-0833; 0093-9147; 16714-904; 47335-760; 68071-4897; 75834-219; 65344-0017; 63629-4534; 65841-671; 50090-5145; 57237-173; 16714-903; 55289-277; 57237-174; 70518-2107; 50090-2886; 75834-217; 16714-905; 50090-5732; 63629-8143; 33342-194; 63187-420; 43353-798; 55111-549; 55111-545; 55111-098; 53002-2361; 70518-2532; 71335-0106; 16714-044; 71335-0383; 33342-195; 71335-1812; 50090-5929; 71335-1642; 72761-018; 71205-369; 71335-0184; 68071-2427; 60429-867; 71335-1471; 63187-177; 70518-2659; 68788-6834; 70518-1010; 0615-8122; 71205-408; 70518-2652; 13668-019; 68071-2588; 71335-1344; 12666-0004; 42816-0836; 55700-914; 70518-1385; 50090-2180; 67046-557; 68788-8068; 65862-405; 0093-7384; 42291-898; 55111-548; 42291-894; 47335-758; 57237-175; 52286-0006; 50090-5725; 0904-6470; 65862-408; 71335-1509; 0008-0837; 50090-5255; 61919-222; 58598-0012; 42291-892; 71785-1008; 68382-034; 71335-1213; 0008-0836; 50268-818; 50771-005; 16714-045; 72189-066; 50090-5930; 55111-455; 71785-1006; 43353-268; 65862-697; 70518-2259; 68071-1566; 60760-304; 45865-864; 71921-173; 55700-816; 50090-5942; 13668-018; 71785-1007; 0904-7076; 53002-2366; 50090-4854; 66651-908; 55154-3362; 63629-2100; 42816-0833; 46708-875; 65862-407; 50771-004; 70518-0742; 70518-2121; 63629-2101; 13668-020; 0615-7621; 50771-002; 68025-081; 0093-7385; 68071-1728; 50090-5890; 65841-672; 65841-673; 50090-3855; 68084-713; 70518-3219; 31722-004; 65862-406; 42291-896; 71335-1864; 68788-6424; 63629-6884; 65841-674; 71335-0185; 68071-4442; 68025-079; 0904-7077; 55111-453; 57451-1207; 0527-2605; 53104-7529; 42291-897; 50090-4853; 60760-187; 55111-546; 68788-8140; 70518-0478; 71921-174; 70518-1907; 71610-018; 0904-7075; 71921-172; 0615-7622; 75834-218; 65862-528; 29033-045; 0527-2604; 13811-715; 0093-7386; 64679-716; 50771-003; 29033-046; 62331-044; 42291-893; 55111-454; 42291-899; 68071-4876; 53002-1361; 71335-1301; 65862-404; 50090-2519; 17511-131; 57237-172; 16714-043; 50090-4568; 52343-133; 52343-132; 71335-1868; 63629-3325
Synonyms Venlafaxine Hydrochloride | Hydrochloride, Venlafaxine | Cyclohexanol, 1-(2-(dimethylamino)-1-(4-methoxyphenyl)ethyl)-, hydrochloride | 1-(2-(dimethylamino)-1-(4-methoxyphenyl)ethyl)cyclohexanol HCl | Wy 45030 | Wy-45030 | Wy45030 | Wy-45,030 | Wy 45,030 | Wy45,030 | Sila-Venlafaxine | Sila Venlafaxine | Effexor | Trevilor | Vandral | Efexor | Venlafaxine | Dobupal
Chemical Information
Molecular Formula C17H28ClNO2
CAS Registry Number 99300-78-4
SMILES CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O.Cl
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Metabolic disorderActivity-regulated cytoskeleton-associated proteinQ9WV31Not AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Dyspnoea22.02.01.004; 02.01.03.002--
Dystonia17.01.03.001--Not Available
Dysuria20.02.02.002--
Ecchymosis24.07.06.002; 23.06.01.001; 01.01.03.001--Not Available
Ejaculation disorder21.03.01.002--
Electrocardiogram QT prolonged13.14.05.004--
Epistaxis24.07.01.005; 22.04.03.001--
Erythema multiforme23.03.01.003; 10.01.03.015--
Gastrointestinal haemorrhage24.07.02.009; 07.12.02.001--Not Available
Hallucination19.10.02.002--
Headache17.14.01.001--
Hepatitis09.01.07.004--Not Available
Hypercholesterolaemia14.08.01.001--Not Available
Hyperhidrosis08.01.03.028; 23.02.03.004--
Hypertension24.08.02.001--
Hypertonia17.05.02.001; 15.05.04.007--Not Available
Hyponatraemia14.05.04.002--
Hypotension24.06.03.002--
Insomnia19.02.01.002; 17.15.03.002--
Interstitial lung disease22.01.02.003; 10.02.01.033--Not Available
Libido decreased21.03.02.005; 19.08.03.001--
Liver function test abnormal13.03.01.013--Not Available
Mania19.16.02.002--
Menstrual disorder21.01.01.004--Not Available
Myalgia15.05.02.001--
Mydriasis17.02.11.003; 06.05.03.004--Not Available
Myoclonus17.02.05.008--Not Available
Nausea07.01.07.001--
Nervousness19.06.02.003--Not Available
Neuroleptic malignant syndrome15.05.04.015; 12.03.01.003; 08.05.01.005; 17.05.02.003--Not Available
The 2th Page    First    Pre   2 3 4    Next   Last    Total 4 Pages